DiaMedica Therapeutics (DMAC) Return on Capital Employed (2019 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Return on Capital Employed of 71.36% for Q1 2026, up 533.0% year-over-year from 11.27% in Q1 2025, and down 12.19% quarter-over-quarter from 63.61% in Q4 2025.
DiaMedica Therapeutics (DMAC) Return on Capital Employed (2019 - 2026) Analysis & Trends
DiaMedica Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 71.36% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 533.0% year-over-year to 71.36%; the TTM figure through Mar 2026 stood at 71.36% (up 533.0% YoY), while the FY2025 annual figure was 70.59%, down 1112.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 71.36%, down from 63.61% in the prior quarter.
- The five-year high for Return on Capital Employed was 31.95% in Q1 2022, with the low at 101.35% in Q2 2025.
- The 5-year median for Return on Capital Employed is 44.82% (2024), against an average of 53.39%.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed surged 3278 bps in 2022, then sank 5653 bps in 2025.
- DiaMedica Therapeutics' Return on Capital Employed stood at 41.73% in 2022, then advanced by 5 bps to 39.85% in 2023, then tumbled by 52 bps to 60.58% in 2024, then decreased by 5 bps to 63.61% in 2025, then retreated by 12 bps to 71.36% in 2026.
- Business Quant data shows DMAC's Return on Capital Employed at 71.36% in Q1 2026, 63.61% in Q4 2025, and 86.18% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | -92.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -92.41% |
| Mar 31, 2026 | -71.36% |
| Dec 31, 2025 | -63.61% |
| Sep 30, 2025 | -86.18% |
| Jun 30, 2025 | -101.35% |
| Mar 31, 2025 | -76.69% |
| Dec 31, 2024 | -60.58% |
| Sep 30, 2024 | -47.87% |
| Jun 30, 2024 | -44.82% |
| Mar 31, 2024 | -43.77% |
| Dec 31, 2023 | -39.85% |
| Sep 30, 2023 | -33.48% |
| Jun 30, 2023 | -39.29% |
| Mar 31, 2023 | -54.20% |
| Dec 31, 2022 | -41.73% |
| Sep 30, 2022 | -36.26% |
| Jun 30, 2022 | -34.60% |
| Mar 31, 2022 | -31.95% |
| Dec 31, 2021 | -29.94% |
| Sep 30, 2021 | -43.66% |